The Science Behind GLP-1 Weight Loss

GLP-1 (glucagon-like peptide-1) is a hormone your gut produces naturally after eating. GLP-1 receptor agonists mimic and amplify this signal with a much longer half-life than the natural hormone.

The brain effect

GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety. When activated by semaglutide or tirzepatide, these receptors reduce hunger signals and increase feelings of fullness — patients consistently describe simply not thinking about food as much.

The gut effect

GLP-1 agonists slow gastric emptying — food moves more slowly from your stomach to your small intestine. This prolongs satiety after meals and blunts post-meal glucose spikes.

The pancreas effect

GLP-1 stimulates insulin secretion in a glucose-dependent manner (only when blood sugar is elevated) and suppresses glucagon. This is why GLP-1s were originally developed as diabetes drugs and why they rarely cause hypoglycemia.

Why tirzepatide works better

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist. GIP (glucose-dependent insulinotropic polypeptide) acts on fat cells and enhances the GLP-1 effect. Clinical trials show tirzepatide producing 20–22% average body weight loss vs 15–17% for semaglutide — a meaningful difference for patients with more weight to lose.

What GLP-1s don't do

They don't preferentially burn fat vs muscle. Protein intake and resistance training remain important to preserve lean mass during rapid weight loss on GLP-1 therapy.